Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,036 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,949 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00901069 | Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma | completed | Phase 1 | 12 | Shams ShakilOTHER | 1 | Oct 17, 2016 | clinicaltrials |
| NCT02810223 | Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia | unknown | Phase 1 | 20 | Beijing Sanwater Biological Technology Co., Ltd.INDUSTRY | 1 | Oct 14, 2016 | clinicaltrials |
| NCT02933775 |
| CD19-redirected Autologous Cells (CAR-CD19 T Cells) |
| unknown |
| Phase 1 |
| 45 |
| RenJi HospitalOTHER |
| 1 |
| Oct 14, 2016 |
| clinicaltrials |
| NCT00714103 | 8-Chloro-Adenosine in Chronic Lymphocytic Leukemia | completed | Phase 1 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 13, 2016 | clinicaltrials |
| NCT00517530 | A Dose-Escalating Study of Obinutuzumab in Patients With B-lymphocyte Antigen (CD20+) Malignant Disease (GAUGUIN) | completed | Phase 1 / Phase 2 | 134 | Hoffmann-La RocheINDUSTRY | 2 | Oct 11, 2016 | clinicaltrials |
| NCT00912899 | A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 | 12 | Cougar Biotechnology, Inc.INDUSTRY | 1 | Oct 7, 2016 | clinicaltrials |
| NCT02141100 | Study of 6-Thioguanine in Combination With 6-Mercaptopurine During Maintenance Therapy of Childhood Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Kjeld SchmiegelowOTHER | 1 | Oct 7, 2016 | clinicaltrials |
| NCT02605356 | Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | BayerINDUSTRY | 11 | Oct 7, 2016 | clinicaltrials |
| NCT01580371 | Safety and Pharmacokinetic Profile of CKD-581(CKD-581) | completed | Phase 1 | 39 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Oct 6, 2016 | clinicaltrials |
| NCT01457417 | A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors | completed | Phase 1 | 32 | Leap Therapeutics, Inc.INDUSTRY | 1 | Sep 28, 2016 | clinicaltrials |
| NCT01718899 | Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma | completed | Phase 1 | 22 | OncoPep, Inc.INDUSTRY | 1 | Sep 28, 2016 | clinicaltrials |
| NCT01829971 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | terminated | Phase 1 | 155 | Mirna Therapeutics, Inc.INDUSTRY | 2 | Sep 27, 2016 | clinicaltrials |
| NCT00047164 | Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy | completed | Phase 1 | 89 | National Institutes of Health Clinical Center (CC)NIH | 1 | Sep 26, 2016 | clinicaltrials |
| NCT02015208 | Ruxolitinib in the Treatment of Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 13 | Sunnybrook Health Sciences CentreOTHER | 1 | Sep 26, 2016 | clinicaltrials |
| NCT02116569 | A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 9 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Sep 26, 2016 | clinicaltrials |
| NCT00446095 | Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma | completed | Phase 1 / Phase 2 | 81 | Rigel PharmaceuticalsINDUSTRY | 1 | Sep 19, 2016 | clinicaltrials |
| NCT01985477 | Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2016 | clinicaltrials |
| NCT01527838 | Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit | completed | Phase 1 | 10 | Fate TherapeuticsINDUSTRY | 1 | Sep 12, 2016 | clinicaltrials |
| NCT02737085 | the Sequential Therapy of CD19-targeted and CD20-targeted CAR-T Cell Therapy for Diffuse Large B Cell Lymphoma(DLBCL) | unknown | Phase 1 / Phase 2 | 40 | Southwest Hospital, ChinaOTHER | 1 | Sep 7, 2016 | clinicaltrials |
| NCT02856685 | A Study of Mitoxantrone Hydrochloride Liposome Infusion | unknown | Phase 1 / Phase 2 | 60 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Aug 22, 2016 | clinicaltrials |
| NCT00891592 | Umbilical Cord Blood Transplant for Hematological Malignancies(UCB) | completed | Phase 1 | 5 | University of PennsylvaniaOTHER | 1 | Aug 19, 2016 | clinicaltrials |
| NCT00434629 | Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant | completed | Phase 1 | 16 | University of PennsylvaniaOTHER | 1 | Aug 17, 2016 | clinicaltrials |
| NCT02281279 | Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | Mayo ClinicOTHER | 0 | Aug 11, 2016 | clinicaltrials |
| NCT00112723 | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma | terminated | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2016 | clinicaltrials |
| NCT00560391 | Dasatinib in Combination With Revlimid (and Dexamethasone) | completed | Phase 1 | 35 | Bristol-Myers SquibbINDUSTRY | 3 | Aug 4, 2016 | clinicaltrials |
| NCT02456350 | Anti-CD19 Chimeric Antigen Receptor (CAR)-Transduced T Cell Therapy for Patients With B Cell Malignancies | unknown | Phase 1 | 36 | Shenzhen Second People's HospitalOTHER | 1 | Aug 3, 2016 | clinicaltrials |
| NCT02457650 | T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies | unknown | Phase 1 | 36 | Shenzhen Second People's HospitalOTHER | 1 | Aug 3, 2016 | clinicaltrials |
| NCT02851589 | Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma | unknown | Phase 1 / Phase 2 | 10 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 1, 2016 | clinicaltrials |
| NCT01078974 | Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia | terminated | Phase 1 | 7 | Steven P. Treon, MD, PhDOTHER | 1 | Jul 25, 2016 | clinicaltrials |
| NCT00407303 | Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL) | completed | Phase 1 / Phase 2 | 24 | Gemin XINDUSTRY | 1 | Jul 21, 2016 | clinicaltrials |
| NCT00006029 | Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 91 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jul 14, 2016 | clinicaltrials |
| NCT00003077 | Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss | completed | Phase 1 / Phase 2 | 63 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 13, 2016 | clinicaltrials |
| NCT02018874 | A Phase Ib Study of the Safety, Tolerability and Efficacy of LY2780301 in Combination With Gemcitabine(INPAKT) | completed | Phase 1 | 52 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jul 12, 2016 | clinicaltrials |
| NCT01871675 | Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies | completed | Phase 1 | 48 | SCRI Development Innovations, LLCOTHER | 1 | Jul 11, 2016 | clinicaltrials |
| NCT01114282 | Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM | completed | Phase 1 | 11 | Stanford UniversityOTHER | 1 | Jul 6, 2016 | clinicaltrials |
| NCT00004239 | 506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment | terminated | Phase 1 | 10 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 4, 2016 | clinicaltrials |
| NCT01297543 | Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia | completed | Phase 1 / Phase 2 | 45 | Cellerant TherapeuticsINDUSTRY | 1 | Jul 1, 2016 | clinicaltrials |
| NCT01284192 | Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma) | completed | Phase 1 | 46 | Astellas Pharma IncINDUSTRY | 1 | Jun 28, 2016 | clinicaltrials |
| NCT02017613 | Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies(PI3K) | completed | Phase 1 | 35 | Rhizen Pharmaceuticals SAINDUSTRY | 2 | Jun 24, 2016 | clinicaltrials |
| NCT00293488 | SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma | completed | Phase 1 | 20 | Progen PharmaceuticalsINDUSTRY | 1 | Jun 23, 2016 | clinicaltrials |
| NCT00990717 | Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies | completed | Phase 1 | 8 | University Health Network, TorontoOTHER | 1 | Jun 23, 2016 | clinicaltrials |
| NCT02315118 | Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies | unknown | Phase 1 / Phase 2 | 18 | National University Hospital, SingaporeOTHER | 1 | Jun 22, 2016 | clinicaltrials |
| NCT00698776 | Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma | completed | Phase 1 | 6 | Yale UniversityOTHER | 1 | Jun 21, 2016 | clinicaltrials |
| NCT01079936 | Lenalidomide and High-Dose Melphalan | completed | Phase 1 / Phase 2 | 61 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 6, 2016 | clinicaltrials |
| NCT00036946 | VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma | completed | Phase 1 | — | Regeneron PharmaceuticalsINDUSTRY | 1 | Jun 3, 2016 | clinicaltrials |
| NCT00045266 | VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's Lymphoma | completed | Phase 1 | — | Regeneron PharmaceuticalsINDUSTRY | 1 | Jun 3, 2016 | clinicaltrials |
| NCT00313053 | Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia | terminated | Phase 1 | 4 | Clare TwistOTHER | 1 | Jun 3, 2016 | clinicaltrials |
| NCT00410982 | Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies | completed | Phase 1 | 145 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 3, 2016 | clinicaltrials |
| NCT01522872 | Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 98 | Threshold PharmaceuticalsINDUSTRY | 1 | Jun 2, 2016 | clinicaltrials |
Data updated 24 days agoSource updated Oct 17, 2016source: clinicaltrials